KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Interest & Investment Income (2021 - 2025)

NovoCure's Interest & Investment Income history spans 5 years, with the latest figure at -$561000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 106.93% year-over-year to -$561000.0; the TTM value through Dec 2025 reached $17.6 million, down 55.38%, while the annual FY2025 figure was $17.6 million, 55.38% down from the prior year.
  • Interest & Investment Income for Q4 2025 was -$561000.0 at NovoCure, down from $6.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $13.2 million in Q4 2023 and bottomed at -$2.0 million in Q3 2021.
  • The 5-year median for Interest & Investment Income is $9.0 million (2023), against an average of $7.6 million.
  • The largest annual shift saw Interest & Investment Income increased 26.51% in 2023 before it plummeted 106.93% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at -$2.0 million in 2021, then surged by 626.0% to $10.4 million in 2022, then rose by 26.51% to $13.2 million in 2023, then crashed by 38.57% to $8.1 million in 2024, then plummeted by 106.93% to -$561000.0 in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Interest & Investment Income are -$561000.0 (Q4 2025), $6.0 million (Q3 2025), and $4.5 million (Q2 2025).